Industry: Healthcare Region: Europe Deal Price: $1 million Deal Method: Equity financing
Introduction to the
The company's shareholders plan to sell some of their shares to raise money.
Details:
Project introduction
The company is a European provider of chronic disease management and digital telemedicine solutions, specializing in the development of multilingual apps and websites to support patients with chronic diseases. The basic solution is free to use for physicians, patients, healthcare professionals, and academic programs.
The company's products are now in use in several hospitals and cancer centers across the country.
Currently, the company develops and runs customizable support programs internally, and collaborates with the pharmaceutical industry to develop specialized software applications, including roche, Pfizer, Novartis, and others, in oncology, immurooncology, CAR-T, tele-cardiology, and more.
Investment highlights
After patients input their daily health status into the software, the AI system directly gives advice through the software on behalf of the doctor, instead of the doctor contacting the patient personally.
Advanced big data learning technology, which can detect patients' symptoms early, and products have also played a role in this outbreak;
Working with large pharmaceutical companies and schools in a variety of fields and projects, with good clinical results;
The law has been amended, and national policies support doctors to issue orders for patients to use digital telemedicine apps, which will be covered by insurance